ONCOLOGY Vol 33 No 7

Dr. Kittles discusses the race-based health disparities in prostate cancer, and one genetic-environmental crossover that is clinically significant.

This review summarizes the major clinical trials that led to the approval of antiangiogenic drugs for ovarian cancer and gives a brief view into novel combinations of bevacizumab with other targeted therapies in an attempt to enhance the efficacy of bevacizumab.

Throughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.

This article summarizes available data for the use of CYP3A4 inhibitors with midostaurin for acute myeloid leukemia.

The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31–June 4 in Chicago, drew more than 32,000 oncology specialists from around the world.

The risk of multiple primary cancers is increasing due to increasing numbers of survivors, long-term side effects of chemotherapy and/or radiation therapy, increased diagnostic sensitivity, and persisting effects of genetic and behavioral risk factors.

ONCOLOGY discussed therapy options for adult acute lymphoblastic leukemia with Dr. Elias Jabbour, MD, Professor of Medicine in the Department of Leukemia at the MD Anderson Cancer Center in Houston, Texas.

Melanoma of the skin is the 19th most common malignant neoplasm worldwide, with 287,723 new cases estimated for 2018 and metastatic melanoma accounting for 4% of all new cases. In recent years, the prognosis of this stage has undergone a dramatic transformation with the advent of immunotherapy and BRAF/MEK targeted therapy.

The US Food and Drug Administration recently approved a new indication for olaparib for maintenance treatment in adult patients with germline or somatic BRCA-mutated advanced epithelial ovarian cancer.